Document is current
Any future updates will be listed below
-
Authors
Lund, Nils
Dahlqvist Leinhard, Olof
Elliott, James M
Peterson, Gunnel
Borga, Magnus
Zsigmond, Peter
Karlsson, Anette
Peolsson, Anneli
-
Funding
Funding for this research was provided by:
Linköping University
- License Information
-
More Information
Article History
Received: 22 November 2022
Accepted: 2 March 2023
First Online: 11 March 2023
Declarations
:
: The study was approved by Linköping University’s Central Ethical Review Board (DNR 2011/262-32). Oral and written informed consent was obtained from every research participant, all personal data was key-coded, data and code key securely stored in different file vaults and handled in accordance with General Data Protection Regulation (GDPR). Participants was insured via the Swedish Legal, Financial and Administrative Services Agency and the research was conducted in accordance with the World Medical Association’s Declaration of Helsinki.
: Not applicable.
: None of the authors has any conflict of interest to disclose. OD Land MB is employees and shareholders of AMRA Medical AB, Linköping, Sweden. AK is a shareholder of AMRA Medical AB. JM has a 3% ownership in Orofacial Therapeutics LC and receives compensation (< USD$10,000/annum for professional development courses with Medbridge).
